Invest in intelligence that delivers

Private Equity Consolidation in Gastroenterology Practices: The Near-Term Outlook and What it Means for Pharma Companies

Spherix Global Insights and Fraser Healthcare are partnering to shed light in this evolving landscape with a new service that will launch this quarter  EXTON, Pa., November 5, 2020 /PRNewswire/ — Spherix Global Insights, a market intelligence firm providing independent coverage of specialty markets such as inflammatory bowel disease (IBD), and Fraser Healthcare, a growth strategy firm […]

Nephrologists Attending the American Society of Nephrology Virtual Meeting Point to New Data on the SGLT2 Inhibitor Class as Being the Most Compelling Presented at the Conference

According to Spherix Global Insights, nephrologists overwhelmingly chose the DAPA-CKD trial as the most compelling among the eight presented during the oral abstract session, “High Impact Clinical Trials” EXTON, Pa., / November 2, 2020 / PRNewswire – With virtual conferences being the standard for the foreseeable future, Spherix Global Insights sought to gather feedback from […]

Eosinophilic Esophagitis, a Complex, Chronic Autoimmune Condition, Awaits FDA-Approved Therapies, Potentially Including a Biologic Option, According to Spherix Global Insights

With both steroid-based and advanced therapies poised for FDA approval in the near term, gastroenterologists’ general satisfaction with current eosinophilic esophagitis treatment options is not optimal  EXTON, Pa., October 29, 2020 /PRNewswire/ — Spherix recently surveyed 103 US gastroenterologists and followed up with ten qualitative interviews (including two with industry key opinion leaders) in order to assess […]

Genentech’s Ocrevus Dominates the Progressive Multiple Sclerosis Market, Although Emerging Agents Could Threaten its Long-Term Reign, According to Patient Chart Data from Spherix Global Insights

Will impressive uptake of Novartis’ Mayzent in the active secondary progressive multiple sclerosis market over the past two years be enough to unseat Ocrevus in the US? EXTON, Pa., October 27, 2020/PRNewswire/ — While the segment of multiple sclerosis (MS) patients with progressive disease remains underserved, numerous recent approvals for relapsing MS (RMS)—including active secondary […]

Rheumatologists and Nephrologists Anxiously Await New Potential Treatments for Systemic Lupus Erythematosus and Lupus Nephritis, According to Spherix Global Insights

Lupus has high unmet needs and a very active pipeline, including AstraZeneca’s anifrolumab, Eli Lilly’s Olumiant, novel TYK-2 inhibitors from Pfizer and Bristol Myers Squibb, as well as a potential label expansion for GlaxoSmithKline’s Benlysta for renal manifestations EXTON, Pa., September 30, 2020 /PRNewswire/ — Rheumatologists have long struggled to effectively treat patients with systemic […]

Want to Try Emgality? What You Should Know

From: MigraineAgain By: Lori Smith   At this time, there is no safety reason for not allowing people to try both Botox and Emgality at the same time. According to Virginia Schobel, Neurology Franchise Head at Spherix Global Insights…(read more).

The Need for Greater Efficacy Drives Increased Switching from Branded TNF Inhibitors to Takeda’s Entyvio, Janssen’s Stelara, and Pfizer’s Xeljanz in US Inflammatory Bowel Disease Market

A newly published report by Spherix Global Insights includes the responses of 216 gastroenterologists and 1,026 audited patient records in the US and reveals the current treatment approach for recently switched ulcerative colitis and Crohn’s disease patients  EXTON, Pa., September 24, 2020 /PRNewswire/ — The 2020 audit included in Spherix’s RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD […]

Gilenya Remains Favorite S1P Receptor Modulator in US, But Zeposia May Catch Up, Survey Finds

From: Multiple Sclerosis News Today By: Marta Figueiredo Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartis’s Gilenya (fingolimod) remains physicians’ favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibb’s Zeposia (ozanimod) are beginning to rise, according to a survey conducted by Spherix Global Insights…(read more).

Sign up for alerts, market insights and exclusive content in your inbox.

Spherix is excited to announce our expansion into an additional, rapidly evolving specialty market:


Throughout 2024, we will be publishing over
10 groundbreaking studies covering a wide range of indications within classical hematology.